This Kalorama Information report – The World Market for Anti-Infectives – focuses on three key segments of treatment:
- Antifungals (Allylamines, Azoles, Polyene Macrolides, Other Antifungals)
- Antibacterials(Aminoglycosides, Carbapenems, Cephalosporins, Macrolides, Penicillins, Quinolones, Sulfonamides, Tetracyclines, Others)
- Antivirals(Nucleoside Analogs, Transcriptase Inhibitors, DNA Polymerase Inhibitors, Protease Inhibitors, Other Antivirals)
The report covers both currently marketed and late stage development products. Revenues for each segment were generated using dollar and unit sales for each product.
A novel approach in this report is that it provides revenue by product type but also the ‘market’ for treatments by type of infection, enabling marketers to research the best markets where a variety of products may be implemented.
The report includes statistical information for infections by type worldwide, with special emphasis on the U.S. and Europe. The market segments provide an overview, description of products on the market, description of products in development, market estimates and forecasts, and competitive analysis of leading providers.
The area of anti-infectives represents an exciting frontier for development of potential life-saving products. However, there are a number of issues and trends that have a direct influence on this market and manufacturers’ ability to successfully operate in the market. The issues and trends affecting this market include:
- Drug Resistance
- HIV Trends, Cost, and Access to Drug Therapy
- Other Immunocompromised Population Issues
- Alliances and Partnerships
- New Developments
- Rx-to-OTC Switches
The information for this report was gathered using both primary and secondary research including comprehensive research of secondary sources such as company literature, databases, investment reports, and medical and business journals focused on the anti-infective industry. Telephone interviews and email correspondence were the primary method of gathering information. For the purpose of this study Kalorama Information conducted interviews with key industry officials, consultants, health care providers, and government personnel. These sources were the primary basis in gathering information specifically relating to revenue and market share data presented in this report. Specific interviews with pharmaceutical company representatives included marketing directors, division managers, and product representatives.
All market data pertains to the world market at the manufacturers’ level. The base year for data was 2011. Historical data was provided for the years 2007 through 2010, with forecast data provided for 2012 through 2015. Compound annual growth rates (CAGRs) are provided for the 2007-2011, 2011-2015 and 2007-2015 periods for each industry segment covered. Competitive analysis is provided for the years 2007 through 2011 with a special focus on 2011. The forecasted market analysis for 2011-2015 was based on probability of approval and sales of products in late stage development, future trends in current product demand, generic penetration, product marketing, and relevant demographic trends.
Companies profiled in this report include:
- Abbott Laboratories
- Bristol-Myers Squibb
- Daiichi Sankyo
- Gilead Sciences
- Johnson & Johnson